e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novartis AG Common Stock
(NY:
NVS
)
153.44
-0.81 (-0.53%)
Official Closing Price
Updated: 7:00 PM EDT, Mar 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis AG Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation
January 14, 2026
Date: January 14, 2026 Viatris Inc. (NASDAQ: VTRS) stands at a critical crossroads in early 2026. After years of functioning as a complex, debt-laden conglomerate formed from the massive merger of...
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS
January 13, 2026
On January 13, 2026, Travere Therapeutics (NASDAQ: TVTX) faced a sharp reversal of fortune as the U.S. Food and Drug Administration (FDA) announced a three-month extension for its review of Filspari...
Via
MarketMinute
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance
January 13, 2026
Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...
Via
PredictStreet
Topics
Economy
Intellectual Property
Novartis AG (NYSE:NVS) Stands Out as a Dependable Dividend Stock with Strong Fundamentals
↗
January 01, 2026
Via
Chartmill
The Evolution of a Giant: A Deep Dive into the ‘New’ Johnson & Johnson (JNJ) in 2026
January 13, 2026
As of January 13, 2026, Johnson & Johnson (NYSE: JNJ) stands at a pivotal juncture in its nearly 140-year history. Once a sprawling conglomerate synonymous with baby shampoo and Band-Aids, the "New...
Via
PredictStreet
Topics
Artificial Intelligence
Bankruptcy
Economy
Why Tempus AI Stock Rose Today
↗
January 12, 2026
The data provider's artificial intelligence-driven solutions are accelerating drug discovery.
Via
The Motley Fool
Topics
Artificial Intelligence
Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution
January 12, 2026
In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom"...
Via
TokenRing AI
Topics
Artificial Intelligence
Is Novartis AG Gaining or Losing Market Support?
↗
January 12, 2026
Via
Benzinga
3 Dividend Stocks to Buy in 2026 and Hold Forever
↗
January 11, 2026
All three offer much more than a regular payout.
Via
The Motley Fool
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
January 09, 2026
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its...
Via
MarketMinute
Topics
Intellectual Property
BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism
January 09, 2026
In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The...
Via
MarketMinute
Topics
Intellectual Property
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs
↗
January 08, 2026
Via
Stocktwits
Topics
Government
Trade War 2.0: Markets Braced as Trump’s 2026 Tariff ‘Salvos’ Reshape the Global Supply Chain
January 08, 2026
As of January 8, 2026, the global financial landscape is undergoing a seismic shift driven by President Trump’s latest round of "tariff salvos." These aggressive trade policies, which dominated the...
Via
MarketMinute
Topics
Economy
Government
World Trade
New Investors: 3 Stocks to Build Your Portfolio Around in 2026
↗
January 08, 2026
These stocks listed here have excellent valuations, promising growth prospects, and they pay dividends.
Via
The Motley Fool
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets
January 07, 2026
The biotechnology sector, long frozen in a capital-starved "biology winter," is showing definitive signs of a seasonal shift. On January 7, 2026, the industry witnessed a significant injection of...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Initial Public Offering
Why Salesforce Rose 16% in December
↗
January 07, 2026
The cloud stock gained after a better-than-expected earnings report.
Via
The Motley Fool
Topics
Artificial Intelligence
Why Did GLUE Stock Surge Over 50% In Premarket Today?
↗
January 07, 2026
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.
Via
Stocktwits
U.S. Scales Back The Number Of Vaccines It Recommends For Every Child
↗
January 05, 2026
Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations.
Via
Stocktwits
Topics
Government
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
January 02, 2026
As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...
Via
PredictStreet
Topics
Economy
Intellectual Property
Stocks
The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis
January 01, 2026
In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position...
Via
TokenRing AI
Topics
Artificial Intelligence
The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery
January 01, 2026
The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model...
Via
TokenRing AI
Topics
Artificial Intelligence
Decoding Life’s Blueprint: How AlphaFold 3 is Redefining the Frontier of Medicine
December 31, 2025
The year 2025 has cemented a historic shift in the biological sciences, marking the end of the "guess-and-test" era of drug discovery. At the heart of this revolution is AlphaFold 3, the latest AI...
Via
TokenRing AI
Topics
Artificial Intelligence
Bonds
Invest Outside the U.S. With These Top International ETFs
↗
December 31, 2025
Compare how fund size, holdings, and portfolio breadth set VEA and SPDW ETFs apart for diversified investors.
Via
The Motley Fool
Topics
ETFs
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report
↗
December 31, 2025
Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January.
Via
Stocktwits
Topics
Economy
Government
The “Operating System of Life”: How AlphaFold 3 Redefined Biology and the Drug Discovery Frontier
December 30, 2025
As of late 2025, the landscape of biological research has undergone a transformation comparable to the digital revolution of the late 20th century. At the center of this shift is AlphaFold 3, the...
Via
TokenRing AI
Topics
Artificial Intelligence
AlphaFold’s Five-Year Reign: 3 Million Researchers and the Dawn of a New Biological Era
December 29, 2025
In a milestone that cements artificial intelligence as the most potent tool in modern science, Google DeepMind’s AlphaFold has officially surpassed 3 million users worldwide. This achievement coincides...
Via
TokenRing AI
Topics
Artificial Intelligence
Climate Change
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
December 29, 2025
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...
Via
MarketMinute
Topics
ETFs
Intellectual Property
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case
↗
December 29, 2025
Novartis (NVS) presents a classic value investing case: a financially strong pharmaceutical leader trading at a discount to peers, with high profitability and a solid dividend.
Via
Chartmill
The Biological Turing Point: How AlphaFold 3 and the Nobel Prize Redefined the Future of Medicine
December 25, 2025
In the final weeks of 2025, the scientific community is reflecting on a year where the boundary between computer science and biology effectively vanished. The catalyst for this transformation was...
Via
TokenRing AI
Topics
Artificial Intelligence
Initial Public Offering
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.